
|Articles|July 1, 2014
Agenus Brain Cancer Vaccine Doubles Survival
Advertisement
said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.
The drug, when given in addition to standard treatment, extended median overall survival in 50 percent of newly-diagnosed glioblastoma multiforme (GBM) patients to two years in a mid-stage study.
Usually GBM patients succumb to the disease in one year.
Original report:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
WHO Publishes GLP-1 Guidelines for Obesity Treatment
2
From Trial Diversity to Telehealth: Advancing Equity and Access in Rural and Underserved Cancer Care
3
Mental Health Care Use After Leaving Medicare Advantage for Traditional Medicare
4
Shaping the Future of Community Oncology Through Sustainable Practices
5













































